Regular ArticlePredictive value of extent and grade of ductal carcinoma in situ in radiologically guided core biopsy for the status of margins in lumpectomy specimens☆
References (26)
- et al.
Controversies in the local management of invasive and non-invasive breast cancer
Cancer Lett
(1995) - et al.
Ductal carcinoma in situ. The success of breast conservation therapy: a shared experience of two single institutional nonrandomized prospective studies
Surg Oncol Clin North Am
(1997) - et al.
The impact of tumor size and histology on local control after breast-conserving therapy
Radiother Oncol
(1988) - et al.
Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up
Hum Pathol
(1998) - et al.
Can the clinical and mammographic findings at presentation predict the presence of an extensive intraductal component in early stage breast cancer?
Int J Radiat Oncol Biol Phys
(1989) - et al.
The diagnostic accuracy of core biopsy in palpable and non-palpable breast lesions
Eur J Radiol
(1997) Future prospects in limited surgery for early breast cancer
Sem Surg Oncol
(1996)- et al.
Clinical and radiological predictors of complete excision in breast-conserving surgery for primary breast cancer
Aust NZ J Surg
(1998) - et al.
Reanalysis and results after 12 years follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer [see comments]
N Engl J Med
(1995) - et al.
Ten-year results in 1070 patients with stages I and II breast cancer treated by conservative surgery and radiation therapy
Cancer
(1995)
Comparison of partial and modified radical mastectomy in the community setting ««10 years later»»
Can J Surg
The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy
Ann Surg
[Prognostic value of determination of the presence and histologic grade of the intraductal component in invasive ductal carcinoma of the breast after conservation treatment]
Lijec Vjesn
Cited by (22)
Mass-forming ductal carcinoma in situ: An ultrasonographic and histopathologic correlation study
2022, Pathology Research and PracticeCitation Excerpt :We found that this group had the significant likelihood of missed invasive carcinoma than that of the other categories on follow-up excision, with an upgrade rate of 35% (p < 0.05). One limitation of our study was that we did not evaluate the significance of DCIS histologic features on CNBs as a predictor of margin status or the maximal pathology in the subsequent excisions, as former studies have already reported on this topic [28–32]. In conclusion, we categorized four mass-forming DCIS groups following US CNB for mass-forming lesions with a diagnosis of DCIS.
Predictive factors associated with involved margins in breast cancer treated with neoadjuvant chemotherapy followed by breast-conserving therapy
2019, Journal of Gynecology Obstetrics and Human ReproductionDiagnostic Pathology: Breast
2017, Diagnostic Pathology: BreastDoes the volume of ductal carcinoma in situ impact the positive margin rate in patients undergoing breast conservation for invasive breast cancer?
2013, Journal of Surgical ResearchCitation Excerpt :Mai et al. studied the extent and grade of DCIS in core needle biopsy specimens and the association with positive surgical margins. Core needle biopsies with at least three foci of low-grade DCIS or at least two foci of high-grade DCIS were associated with a greater likelihood of positive or close margins in the subsequent lumpectomy specimens [17]. Core biopsy pathology was not available in the present study, but future prospective studies may be helpful in more clearly delineating the pathologic features of DCIS in core specimens and the final surgical margin outcomes.
- ☆
Correspondence to: Dr K. T. Mai, Anatomical Pathology, The Ottawa Hospital, Civic Campus, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9. Tel: +1 (613) 761-4344; Fax: +1 (613) 761-4846; E-mail: [email protected]